华东医药涨2.06%，成交额1.95亿元，主力资金净流入637.63万元

Core Viewpoint - Huadong Medicine's stock price has shown a mixed performance in recent months, with a year-to-date increase of 20.43% but a decline over the last 60 days by 9.22% [1] Financial Performance - For the period from January to September 2025, Huadong Medicine achieved a revenue of 32.664 billion yuan, representing a year-on-year growth of 3.77% [2] - The net profit attributable to shareholders for the same period was 2.748 billion yuan, reflecting a year-on-year increase of 7.24% [2] Shareholder Information - As of September 30, 2025, the number of Huadong Medicine's shareholders was 68,800, a decrease of 1.50% from the previous period [2] - The average number of tradable shares per shareholder increased by 1.53% to 25,466 shares [2] Dividend Distribution - Since its A-share listing, Huadong Medicine has distributed a total of 8.873 billion yuan in dividends, with 3.771 billion yuan distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder, holding 52.0036 million shares, an increase of 12.1653 million shares from the previous period [3] - China Securities Finance Corporation remained the fourth-largest shareholder with 22.1868 million shares, unchanged from the previous period [3] - Other notable changes include a decrease in holdings by the top ten circulating shareholders, such as the reduction of 4.3243 million shares by the China Europe Medical Health Mixed A fund [3]